SPLITOAK STRATEGIES LLC for ALKERMES, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program Proposed Rule (CMS-2434-P) -- and operational and patient access challenges with stacking policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH KUEHL EGGE | — |
Health Issues HCR
Awareness of the need for access to all FDA-approved medications for treatment of substance use disorder; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments for substance use disorder and alcohol use disorder; Initiatives to promote the use of relapse prevention post detoxification; H.R.4531/S.3393 Support for Patients and Communities Reauthorization Act; Advance the use and funding of FDA-approved medicines to treat serious mental illness in criminal justice and public health settings
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH KUEHL EGGE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.